Arvelle Announces Partnership with Durbin Across Europe
Zug, Switzerland, 17 August 2020 – Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to…
Cenobamate Designated Promising Innovative Medicine (PIM) by the UK’s MHRA for Treatment of Drug-Resistant Focal-Onset Seizures in Adults
PIM designation is an early indication that cenobamate is a promising candidate for the MHRA’s Early Access to Medicine Scheme Milestone further…
Arvelle to Present at Jefferies Virtual 2020 Healthcare Conference
Zug, Switzerland, 1 June 2020 – Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to…
Arvelle Announces Closing of Final Tranche of Series A Financing Round
Brings the total financing to $207.8m Triggered by successful filing and validation of the MAA for cenobamate Zug, Switzerland, 26 May 2020 –…
Results of a Randomised Study Showing that Adjunctive Cenobamate Significantly Improved Seizure control in Adults with Uncontrolled Focal Seizures Published in Neurology 1
28% of patients receiving cenobamate achieved seizure-freedom (zero seizures) during the study’s maintenance phase, versus 9% receiving placebo1…
SK Life Science, Inc. Announces US Availability of XCOPRI® (cenobamate tablets) for the Treatment of Partial (Focal) Onset Seizures in Adults with Epilepsy
Arvelle Therapeutics has exclusive rights to develop and commercialize cenobamate in Europe Zug, Switzerland, 12 May 2020 – Arvelle…
Arvelle Announces European Medicines Agency Acceptance of the Marketing Authorization Application (MAA) for Cenobamate
The MAA seeks authorisation for the adjunctive treatment of focal-onset seizures in adult patients with epilepsy Zug, Switzerland, 26 March 2020…